Indian imports threatened by regulatory body problems
This article was originally published in Clinica
There are concerns that a shortage of staff and expertise at India's medtech and pharma regulatory body, the Central Drugs Standard Control Organisation (CDSCO), will lead to a blocking of imports.
You may also be interested in...
The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.
Through its partnership with majority stakeholder Nanjing King-Friend Biochemical Pharmaceutical, Meitheal Pharmaceuticals has received FDA approval for enoxaparin, a generic rival to Lovenox.